A5032127031- Glycosylation and Glycoproteins Research
- Monoclonal and Polyclonal Antibodies Research
- Protein purification and stability
- Chromosomal and Genetic Variations
- Mesenchymal stem cell research
- RNA and protein synthesis mechanisms
- SARS-CoV-2 and COVID-19 Research
- Chronic Lymphocytic Leukemia Research
- vaccines and immunoinformatics approaches
- Galectins and Cancer Biology
- Bacillus and Francisella bacterial research
- Genomics and Chromatin Dynamics
Dokuz Eylül University
2019-2023
Izmir University
2019-2023
Abstract Recombinant protein-based SARS-CoV-2 vaccines are needed to fill the vaccine equity gap. Because protein-subunit based easier and cheaper produce do not require special storage/transportation conditions, they suitable for low-/middle-income countries. Here, we report our development studies with receptor binding domain of Delta Plus strain (RBD-DP) which caused increased hospitalizations compared other variants. First, expressed RBD-DP in Pichia pastoris yeast system upscaled it a...
Abstract Single chain antibody fragments (scFvs) are favored in diagnostic and therapeutic fields thanks to their small size the availability of various engineering approaches. Linker between variable heavy (V H ) light L chains scFv covalently links these domains it can affect scFv’s bio-physical/chemical properties vivo activity. Thus, linker design is important for a successful construction, flexible linkers preferred proper pairing V –V . The flexibility determined by length sequence...
The number of therapeutic antibodies in preclinical, clinical, or approved phases has been increasing exponentially, mostly due to their known successes. Development antibody engineering methods substantially hastened the development antibodies. A variety protein techniques can be applied improve afinity and/or biophysical properties such as solubility and stability. Antibody fragments (where all some parts constant regions are eliminated while essential antigen binding region is preserved)...
Understanding the determinants of antibody specificity is one challenging tasks in development. Monospecific antibodies are still dominant approved therapeutics but there a significant body work to show that multispecific can increase overall therapeutic effect. Dual-specific or "Two-in-One" bind two different antigens separately with same antigen-binding site as opposed bispecifics, which simultaneously through separate units. These nonstandard dual-specific were recently shown be promising...